ICD-10 Coding for Uterine Leiomyosarcoma(C54.1, C54.1U, C54.2)
Comprehensive guide to ICD-10 coding for uterine leiomyosarcoma, including primary and differential codes, documentation requirements, and common pitfalls.
Complete code families applicable to Uterine Leiomyosarcoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C54.2 | Malignant neoplasm of myometrium | Use when the tumor is confirmed to originate in the myometrium. |
|
| C55 | Malignant neoplasm of uterus, part unspecified | Use when documentation does not specify the uterine subsite. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutUterine Leiomyosarcoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Uterine Leiomyosarcoma.
Documenting 'malignant uterine tumor' without specifying the site.
Impact
Clinical: May lead to inappropriate treatment planning., Regulatory: Non-compliance with coding specificity requirements., Financial: Potential for reduced reimbursement.
Mitigation
Ensure detailed site documentation in medical records., Educate providers on the importance of specifying tumor location.
Using C55 when the site is specified as myometrium.
Impact
Reimbursement: Incorrect coding may lead to lower reimbursement rates., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data for clinical and research purposes.
Mitigation
Use C54.2 when the tumor is confirmed in the myometrium.
Use of unspecified codes
Impact
High use of C55 without site specification can trigger audits.
Mitigation
Encourage detailed documentation of tumor site.